Anabolic Agents: A New Chapter in the Management of Osteoporosis

Osteoporosis in postmenopausal women has until now been treated with antiresorptive agents, reducing the incidence of fragility fracture by approximately 50%. Clinical research has led to the development of new anabolic therapies capable of increasing the production of bone matrix by osteoblasts and reversing microarchitectural deterioration, resulting in major improvements in both bone quality and bone quantity. Teriparatide, a recombinant …